STIM · XBRL financial data

Neuronetics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (STIM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	49,244	55,312	65,206	71,348	74,890	149,157
Cost of goods and services sold	11,554	11,653	15,483	19,643	20,729	76,849
Gross profit	37,690	43,659	49,723	51,705	54,161	72,308
Research and development	9,201	7,923	9,336	9,515	12,771	6,584
General and administrative	18,236	25,554	25,516	25,426	30,322	49,702
Total operating expenses	59,999	71,223	84,834	82,259	88,724	103,744
Operating income (loss)	(22,309)	(27,564)	(35,111)	(30,554)	(34,563)	(31,436)
Interest expense	4,522	4,019	4,251	5,424	7,286	8,415
Other income (expense)	302	390	2,203	5,789	2,549	716
Net income (loss)	(27,453)	(31,193)	(37,159)	(30,189)	(43,708)	(38,998)
Earnings per share, basic USD per share	(1.46)	(1.22)	(1.38)	(1.05)	(1.38)	(0.59)
Earnings per share, diluted USD per share	(1.46)	(1.22)	(1.38)	(1.05)	(1.38)	(0.59)
Weighted average shares, basic thousands of shares	18,835	25,479	26,900	28,658	31,734	65,951
Weighted average shares, diluted thousands of shares	18,835	25,479	26,900	28,658	31,734	65,951

Fiscal years (STIM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	48,957	94,141	70,340	59,677	18,459	28,134
Accounts receivable	7,166	7,706	13,591	15,782	23,355	16,469
Inventory	3,720	6,563	8,899	8,093	4,248	4,327
Prepaid and other current assets	2,186	3,090	2,174	4,766	6,846	2,922
Total current assets	65,012	115,331	98,769	93,793	58,122	61,551
Property and equipment, net	730	1,220	1,991	2,009	6,242	4,466
Right-of-use asset	3,418	3,884	3,327	2,773	27,093	23,560
Goodwill	—	—	—	—	18,634	23,622
Total assets	78,657	141,223	116,884	115,831	140,903	141,551
Accounts payable	3,749	4,299	2,433	4,752	11,077	10,739
Accrued liabilities	7,319	8,233	14,837	12,595	12,818	12,316
Current portion of long-term debt	—	—	13,125	—	—	—
Total current liabilities	13,682	15,703	33,199	19,812	31,265	30,521
Long-term debt	34,620	35,335	22,829	59,283	55,151	65,807
Lease liability, non-current	3,121	3,539	2,967	2,346	22,686	18,935
Total liabilities	53,164	56,048	59,824	81,641	109,104	115,311
Accumulated deficit	(277,540)	(308,733)	(345,892)	(376,081)	(419,789)	(458,787)
Total stockholders' equity	25,493	85,175	57,060	34,190	27,706	22,378
Total liabilities and equity	78,657	141,223	116,884	115,831	140,903	141,551
Common shares outstanding (cover page) thousands of shares	25,408	26,628	28,363	29,756	65,815	69,277

Fiscal years (STIM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(27,453)	(31,193)	(37,159)	(30,189)	(43,708)	(38,998)
Stock-based compensation	4,404	7,869	8,746	7,319	5,602	6,848
Depreciation and amortization	941	1,060	1,648	2,006	2,073	3,465
Net cash from operating activities	(28,390)	(27,983)	(30,739)	(32,038)	(30,997)	(20,374)
Net cash from investing activities	(730)	(9,839)	6,731	(1,322)	(2,413)	(801)
Proceeds from issuing common stock	—	80,972	—	—	—	—
Proceeds from long-term debt	41,360	—	—	25,000	57,479	10,000
Repayments of long-term debt	38,860	—	—	1,200	60,000	—
Net cash from financing activities	2,369	83,006	207	22,697	(6,808)	35,850

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Neuronetics	22,106	41,962	1,238*	77.7M	—	Q3 FY26 10-QSep 30, 2026
Picard Medical	38	2,954	(1,352)*	2.3M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Lakeland Industries	17,901	50,139	(404)*	9.9M	—	Q2 FY27 10-QJul 31, 2026
InfuSystem Holdings	964	36,933	6,777*	19.9M	—	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
KORU Medical Systems	8,288	12,045	216*	46.2M	—	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
LENSAR	13,565	16,495	(127)*	12.3M	106.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.